Key Points
- CEO Markus Warmuth sold 5,466 shares on March 2 at an average price of $17.92 for $97,950.72, cutting his position by 0.88% to 613,471 shares (worth ~ $10.99M); he also sold 5,466 shares on Jan. 7 at $23.49.
- GLUE shares traded near $18.07 with a market cap of $1.18B and roughly 79.96% institutional ownership, while analysts hold a consensus "Moderate Buy" rating with an average target of $31.33 and several firms issuing buy/outperform views.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) CEO Markus Warmuth sold 5,466 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $17.92, for a total transaction of $97,950.72. Following the transaction, the chief executive officer owned 613,471 shares in the company, valued at approximately $10,993,400.32. The trade was a 0.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Markus Warmuth also recently made the following trade(s):
- On Wednesday, January 7th, Markus Warmuth sold 5,466 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $23.49, for a total transaction of $128,396.34.
Monte Rosa Therapeutics Stock Performance
Shares of GLUE stock traded down $0.54 during trading on Thursday, hitting $18.07. The company had a trading volume of 392,992 shares, compared to its average volume of 1,777,384. The firm has a market capitalization of $1.18 billion, a P/E ratio of 56.47 and a beta of 1.63. Monte Rosa Therapeutics, Inc. has a one year low of $3.50 and a one year high of $25.77. The stock's 50-day moving average price is $19.97 and its 200 day moving average price is $13.90.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. AQR Capital Management LLC bought a new stake in Monte Rosa Therapeutics during the 1st quarter worth $1,065,000. Goldman Sachs Group Inc. boosted its position in Monte Rosa Therapeutics by 122.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company's stock worth $1,652,000 after buying an additional 196,238 shares during the period. Acadian Asset Management LLC bought a new stake in Monte Rosa Therapeutics during the 1st quarter worth approximately $76,000. Los Angeles Capital Management LLC acquired a new position in Monte Rosa Therapeutics in the 2nd quarter valued at approximately $89,000. Finally, Geode Capital Management LLC raised its stake in shares of Monte Rosa Therapeutics by 12.0% during the second quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company's stock valued at $5,071,000 after acquiring an additional 120,098 shares during the last quarter. 79.96% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of research firms recently commented on GLUE. Wedbush reaffirmed an "outperform" rating and issued a $37.00 price target on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Jefferies Financial Group restated a "buy" rating and issued a $31.00 target price on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Wells Fargo & Company upped their price target on shares of Monte Rosa Therapeutics from $22.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, January 8th. Piper Sandler reiterated an "overweight" rating and set a $37.00 price target (up from $27.50) on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 14th. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Monte Rosa Therapeutics in a research report on Monday, December 29th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $31.33.
Get Our Latest Stock Report on GLUE
Monte Rosa Therapeutics Company Profile
(
Get Free Report)
Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.
The company's main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
